FDA, COVID-19 vaccine
Digest more
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
The agency will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to green-lighting shots that have been recommended broadly to the public.
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy
President Donald Trump’s administration is slated to lay out its approach to Covid vaccination at an event Tuesday that could spell major changes in what is required to get regulatory approval for immunizations.
Novavax finally won approval of a Covid-19 vaccine after facing setback after setback that caused the stock to plunge more than 50% in the past year.The stock surged 20% to $8.10 in early trading Monday.
Explore more
1d
Asianet Newsable on MSNNovavax Wins FDA Approval For COVID-19 Vaccine: Retail Calls For Buyback And Bigger MovesThe pharma company secured FDA clearance to manufacture and distribute its COVID-19 vaccine Nuvaxovid for adults and at-risk groups, with no advisory committee hurdles.